Acquisition of drug resistance is one of the main obstacles encountered in cancer chemotherapy. Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicin-resistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. In addition, Northern-blot analysis revealed an eight fold upregulation of the imprinted H19 mRNA in R-HepG2 cells. H19 knockdown by transfection with antisense H19 oligonucleotides suppressed the MDR1/P-glycoprotein expression, increased the cellular doxorubicin accumulation level and sensitized doxorubicin toxicity in both HepG2 parent cells and R-HepG2 cells. Results from methylation-specific polymerase chain reaction analysis indicated that the MDR1 gene promoter was hypomethylated in R-HepG2 cells. Antisense H19 oligonucleotides transfection induced a marked increase in the percentage of MDR1 promoter methylation and decrease in MDR1 expression in R-HepG2 cells. Thus, the H19 gene is believed to induce P-glycoprotein expression and MDR1-associated drug resistance at least in liver cancer cells through regulation of MDR1 promoter methylation.
The H19 gene is one of the first group of genes that proved to be paternally imprinted and maternally expressed. The gene is mapped to human chromosome 11p15.5 and is transcribed by RNA polymerase II (Glaser et al., 1989) . The transcript is then capped, spliced and transported to cytoplasm but not translated (Eddy, 2001) . The protein translated from the endogenous H19 messenger RNA (mRNA) has so far not been detected. It is therefore believed that H19 may function as a riboregulator that exerts its biological function as RNA. Despite the discovery of H19 by Pachnis et al. (1984) for about a decade ago, its biological functions are not well understood. H19 is abundantly expressed in human placenta and embryonic tissues but is repressed in almost all adult tissues. This pattern of expression suggests an involvement of H19 in fetal development. Although accumulating evidences suggest that H19 gene may play a role in oncogenesis (Lottin et al., 2002a) , results from other studies suggest that it possesses a tumor-suppressor activity (Hao et al., 1993) .
Acquisition of drug resistance is one of the main obstacles encounters in cancer therapy and it is usually associated with the expression of multi-drug resistance 1 (MDR1) gene, which encodes for a 170 kDa membranebound P-glycoprotein. P-glycoprotein belongs to the ATP-binding cassette family and functions as a drug efflux pump that effectively reduces intracellular drug level to maintain cell survival and drug tolerance. Overexpression of H19 mRNA, accompanied with an upregulation of a 95 kDa membrane glycoprotein termed p95 but not P-glycoprotein or other multi-drug resistance proteins, was observed in multi-drug-resistant human breast carcinoma MCF7/AdrVp cells and lung carcinoma NCI-H1688 cells (Doyle et al., 1996) . Although this may hint for the possible interaction between H19 and the p95 protein in cells, the role of H19 in inducing drug resistance is however yet to be confirmed. To study whether H19 may participate in drug resistance in human liver cancer cells, the H19 level in human hepatocellular carcinoma HepG2 cells and its doxorubicin-resistant subline R-HepG2 cells was compared. R-HepG2 cells are more resistant to common anticancer drugs, for instance, doxorubicin, etoposide, vincristine and Taxol, than the HepG2 parent cells (data not shown). By Northern-blot analysis, an about eight fold increase in H19 mRNA level was observed in R-HepG2 cells (Figure 1a ). To investigate whether the doxorubicin resistance phenotype in R-HepG2 cells was related to H19 overexpression and to prove that the H19-mediated drug resistance is not limited to HepG2 cells, antisense H19 oligonucleotides were employed to knockdown H19 expression in HepG2 cells as well as in hepatocellular carcinoma Hep3B cells and SK-Hep-1 cells (Cell lines information is in Supplementary Table  1) . The doxorubicin sensitization effect after H19 gene knockdown was demonstrated in HepG2 parent cells, R-HepG2 cells, Hep3B cells and SK-Hep-1 cells, whereas the effect was not observed in those transfected with sense H19 oligonucleotides (Figure 1b and Supplementary Figure 1a) . H19 gene knockdown resulted in about 2-, 3.4-and 3-fold decrease in doxorubicin IC 50 in HepG2, R-HepG2 and Hep3B cells, respectively (Figure 1c) . Moreover, similar kind of doxorubicin sensitization effect was also observed in HepG2 cells transfected with H19 small-interference RNA (siRNA) ( Supplementary  Figure 2) , whereas increase in doxorubicin resistance was seen in cells with H19 gene transfection (Supplementary Figure 3) . The study suggested that H19 might regulate drug sensitivity, at least in liver cancer cells.
To identify the underlying mechanisms for H19 regulation of drug resistance in HepG2 cells, the expressions of H19-related imprinted genes p57(Kip2) and IGF-II, as well as a H19-regulated gene, thioredoxin, were examined. The expressions of IGF-II and p57(KIP2) are closely related to H19 in the process of tumor progression. IGF-II and H19 are coordinately regulated imprinted genes and act in an antagonistic manner in normal cells. Altered transcription of H19 and IGF-II contributed to the progression of HCC and other cancers such as bladder and breast cancer. On the other hand, p57(KIP2) expression seems to be upregulated with H19 in both normal and tumor tissues (Liu et al., 1997; Vernucci et al., 2004) . By proteomic analysis, thioredoxin was found to be regulated at the posttranscriptional level by H19 in human cancerous mammary epithelial cells MDA-MB-231 (Lottin et al., 2002b) . By Northern blot analysis, an about 1.9-fold increase in p57(KIP2) mRNA level was observed in RHepG2 cells, whereas there was no apparent difference in IGF-II and thioredoxin expression levels between the parent cells and R-HepG2 cells (Figure 2a ). To examine whether doxorubicin resistance phenotype in R-HepG2 cells was related to p57(KIP2) overexpression, antisense oligonucleotides were employed to knockdown the expression of p57(KIP2). By 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, p57(KIP2) knockdown did not show any apparent doxorubicin sensitization effect in both HepG2 cells and R-HepG2 cells (data not shown). Results suggested that p57(KIP2), IGF-II and thioredoxin might not play an essential role in mediating H19 effect on doxorubicin sensitivity of HepG2 cells.
Selection of cultured mammalian cancer cells with anticancer drug may induce resistance to that drug and often exhibit a multi-drug resistance phenotype. Northernand Western-blot analysis indicated that there was no significant difference in mRNA and protein levels of drug resistance-related genes such as MRP1 and GST-p in HepG2 parent cells and R-HepG2 cells. However, an approximately seven-to eightfold increase in MDR1 mRNA and P-glycoprotein levels was observed in RHepG2 cells as compared to the parent cells (Figure 2b  and c) . Furthermore, the drug resistance in R-HepG2 cells was partially overcome by P-glycoprotein inhibitor verapamil (data not shown). The results therefore indicated that MDR1 may play a major role in drug resistance in R-HepG2 cells. The overexpression of both H19 and MDR1 in drug-resistant R-HepG2 cells The basal mRNA levels and (c) the protein levels of MRP1, MDR1, GST-p and Trx in HepG2 parent cells and R-HepG2 cells. mRNA and protein levels were detected by Northern-and Western-blot analysis, respectively. (d, e) The effect of H19 oligonucleotides transfection on H19, MDR1 and MRP1 mRNA levels (d) and P-glycoprotein, MRP1 and Trx protein levels (e) in HepG2 parent and R-HepG2 cells. The cells were first transfected with sense (S) or antisense (AS) H19 oligonucleotides before RNA or protein extraction. Relative expression of mRNA or protein was shown below each band. C: the cells without H19 oligonucleotides transfection. Pgp; P-glycoprotein. cDNA probes for Northern-blot hybridization were obtained from gel purification of PCR products amplified with MRP, MDR1 and GST-p specific primers. Primer sequences and PCR conditions are available upon request. For Western-blot analysis, membranes were probed with primary antibodies against MRP1, MDR1, Trx, or GST-p at room temperature for 2 h, washed extensively with 0.1% Tween-20 in phosphate-buffered saline, and then incubated with the respective secondary antibodies conjugated with horseradish peroxidase at 1:10 000 dilution. The signals were visualized with enhanced chemiluminescence.
prompts to suggest the hypothesis that H19 may modulate the MDR1 level in regulation of drug sensitivity of cells. To find out the relationship between H19 and P-glycoprotein expression in doxorubicin resistance, the levels of MDR1 mRNA and P-glycoprotein were examined by Northern-and Western-blot analysis, respectively, after H19 knockdown. Transfection with antisense but not sense H19 oligonucleotides suppressed the MDR1 mRNA and P-glycoprotein levels in both HepG2 parent cells and R-HepG2 cells. Similar results were also observed in Hep3B cells and also for H19 siRNA transfection (Supplementary Figure 2) . On the contrary, the H19 knockdown did not have any effect on MRP1 mRNA and protein expressions (Figure  2d and e). It is therefore believed that H19 may act through MDR1 to regulate drug sensitivity of cells. To confirm this hypothesis further, flow cytometric analysis of doxorubicin accumulation in cells after doxorubicin exposure was studied as P-glycoprotein-associated resistance is primarily believed to be due to increase in drug efflux by the protein. Compared with the initial cellular doxorubicin accumulation level, about 40% of cellular doxorubicin still remained in HepG2 parent cells 3 h after doxorubicin treatment, and it was only 27% in R-HepG2 cells. Results suggested that more doxorubicin was pumped out in the P-glycoprotein overexpressed R-HepG2 cells than that in the parent cells. H19 knockdown suppressed P-glycoprotein ( Figure 2e ) and subsequently reduced drug efflux (as indicated by increased doxorubicin accumulation level) in both HepG2 parent cells and R-HepG2 cells (Table 1) . Compared with no transfection control, H19 knockdown resulted in a 64 and 98% increase of cellular doxorubicin level in HepG2 parent cells and R-HepG2 cells, respectively, whereas the sense oligonucleotides transfection did not show any effect. Results supported the idea that H19 might regulate P-glycoprotein expression which in turn modulates the doxorubicin accumulation level in HepG2 cells. The cells were first transfected with 200 nM sense or antisense H19 oligonucleotides for 4 h at 371C, followed by an exposure to 5 mg/ml of doxorubicin for 1 h and then in drug-free medium for 3 h. The cellular level of doxorubicin was assessed in terms of fluorescent intensity with excitation at 488 nm and emission at 570 nm on a FACSort flow cytometer. A total of 10 000 events were collected in each analysis. Promoter methylation is one of the major factors for regulation of the expression of MDR1 gene. Hypomethylation of CpG sites at MDR1 promoter region, accompanied with P-glycoprotein overexpression, was observed in patients with acute myeloid leukemia and bladder cancer as well as in cultured-selected vincristineresistant human epidermoid KB3-1 cells (Nakayama et al., 1998; Kusaba et al., 1999; Tada et al., 2000) . Cytotoxic stresses caused by anticancer drug after cancer chemotherapy and/or in vitro selection of cancer cells induce demethylation of MDR1 promoter, subsequently P-glycoprotein overexpression (Baylin et al., 1998; Kusaba et al., 1999) . Modification of the methylation status of the promoter may at least be one of the ways for H19 to regulate the expression of the genes downstream. To reveal the molecular mechanism for H19 regulation of MDR1 expression, the methylation status of MDR1 promoter in HepG2 cells was examined by methylation specific (MSP) and unmethylation specific (USP) PCR. The MDR1 gene promoter was hypomethylated in R-HepG2 cells; about 50% of CpG island was found to be methylated in R-HepG2 cells, compared with 88% in HepG2 parent cells. On the other hand, H19 knockdown by antisense H19 oligonucleotides transfection markly increased the MDR1 promoter methylation level (50 to about 85% methylation) in R-HepG2 cells and slightly in HepG2 parent cells (from 89 to 95%). In the case of sense oligonucleotides, the transfection did not demonstrate any effect (Figure 3a) . Furthermore, as indicated by the results from Figure 3a and b, there was an inverse correlation between the extent of MDR1 promoter methylation and MDR1 expression level in HepG2 cells. Demethylation of MDR1 promoter by treatment with DNA methyltransferase inhibitor 5 0 -aza-deoxycytidine (5 0 -aza-dc) for 48 h resulted in a 1.8-fold and six fold reduction in MDR1 promoter methylation in HepG2 parent cells and RHepG2 cells, respectively (Figure 3a) . Treatment of cells with 5 0 -aza-dc for 48 h increased MDR1 mRNA expression and also the doxorubicin resistance in both HepG2 and R-HepG2 cells (Figure 3b and c) . Thus, H19 might regulate MDR1 and its associated drug resistance by altering the degree of MDR1 promoter methylation in HepG2 cells possibly through the DNA methyltransferases in HepG2. DNA methylation is known to be critical in the processes like genetic imprinting, cancer development, etc. H19 is known to be involved in genetic imprinting and cancer development even though the underlying mechanism is yet to be defined. The findings in the present study about the regulatory role of H19 in MDR1 promoter methylation may provide a new insight in future study of H19 function in cells. Furthermore, the study may also help explore a new way to improve the efficacy of cancer chemotherapy.
